Acceler8 Ventures proposes all-share offer for IIG at £600m

Proposed all-share offer uses an exchange ratio of 2.6052 AC8 shares per IIG share, implying an approximate valuation of IIG at £600m based on AC8's 80p close on April 7. Under the terms IIG shareholders would hold ~99.01% of the combined group's ordinary share capital (AC8 ~0.99%) after a planned AC8 bonus issue; AC8 has irrevocable undertakings covering 59,035,785 IIG shares (~24.59%). AC8 also plans to raise ~£1m via unsecured 8% convertible loan notes due 2026 that convert at 34p per AC8 share on completion. AC8 must announce a firm intention or withdraw by 5:00pm on May 6, 2026.

Analysis

The structural outcome embedded in the proposed transaction creates an asymmetric payoff: holders of the acquisitive shell are left with a token minority while the target’s shareholders gain scale and a mainstream listing that can re-rate on liquidity and multiple expansion. Second-order beneficiaries include brokers, corporate advisers and index-tracking products that pick up newly eligible equity; rival closed-end and specialist-fund managers face renewed margin pressure as the combined group competes for institutional fund flows.

Near-term execution risk is dominated by financing and shareholder approval pathways rather than commercial integration — the convertibles and ad-hoc capital raise increase the probability of headline volatility in the coming weeks. Key reversal scenarios that would unwind the re-rate are a failed financing, credible minority litigation, or a decision by the shell to walk away; any of these would compress the combined valuation rapidly.

From a competitive-dynamics perspective, the move to a mainstream listing will force a re-benchmarking to commercial-company peers, exposing underlying asset-management fees and costs to direct comparison; if realized margins fall to peer medians, the uplift to NAV multiples could be modest and take multiple quarters to materialize. Conversely, operational synergies are unlikely to be the primary value driver — the trade is fundamentally a liquidity/market-access revaluation with binary execution risk.

The contrarian angle is that the market is underweight the dilution and governance frictions baked into the transaction mechanics rather than overestimating the listing premium: cheap emergency financing and pre-admission equity gymnastics raise the bar for a clean arbitrage. That makes a small, hedged exposure attractive versus risking unhedged long positions in the acquiring shell.

Key Decisions for Investors

• Buy IIG (IIG) — tactical long, 3–6 month horizon. Size 1–3% of portfolio, target 20–35% upside if scheme is approved and re-rating occurs; hard stop at 10–12% absolute loss. Rationale: capture liquidity/valuation re-rate while limiting exposure to deal-failure noise.
• Short the shell (AC8) — directional short or buy puts, 1–3 month horizon. Size 0.5–1% of portfolio (higher if using options) with asymmetric upside if financing stumbles; set a tight stop if a firm offer is announced. Rationale: capital raise and convertibles materially increase downside for legacy holders and create headline volatility.
• Pair trade: long IIG / short AC8 (delta-neutral notional), 3 months. Use equal notional cash or options structures to isolate deal execution risk; expect positive carry if the market prices target’s listing premium ahead of execution. Rationale: isolates merger/arbitrage premium while hedging macro/systematic risk.
• Event hedge: buy short-dated AC8 puts or sell AC8 covered calls to monetize elevated volatility around financing/deadline windows. Keep exposure small and use options to cap tail loss from unexpected successful bid-induced rerates.